Zacks Investment Research·1d ago
SOLV Q3 Earnings Beat Estimates Despite ERP-Related Revenues DeclineSolventum beats Q3 earnings estimates despite an ERP-driven revenue decline, raises its 2026 EPS outlook and advances its portfolio transformation.
Solventum's fundamental outlook is constrained by flat revenue growth (ranging from -3.7% to +3.8% over the past two years) and deteriorating cash generation, with free cash flow turning negative at -$129M in 2026Q2 versus +$340M in 2024Q1.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth has stalled near zero (latest quarter +2.2%), while gross margin improved to 58.2% but operating margin compressed to 8.2% from 18.9% in 2024Q1, reflecting a 55% rise in SG&A costs.
Solventum Corporation has a rich history of over 70 years in healthcare innovations, positioning it as a leader in the medical instruments and supplies sector.
With $8.3 billion in sales in 2024, Solventum demonstrates robust financial health and market presence.
Bullish investment theses and recommendations to hold SOLV stock indicate strong analyst confidence in its growth potential.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | $1.45+8.2% vs $1.34 | $1.9B+0.9% vs $1.9B |
Q3 2026 Aug 5, 2026 | $2.55+34.2% vs $1.90 | $2.2B+2.6% vs $2.2B |
Q2 2026 May 5, 2026 | $1.48+9.6% vs $1.35 | $2.0B+2.0% vs $2.0B |
Q1 2026 Feb 26, 2026 | $1.57+4.7% vs $1.50 | $2.0B+1.8% vs $2.0B |
Solventum beats Q3 earnings estimates despite an ERP-driven revenue decline, raises its 2026 EPS outlook and advances its portfolio transformation.
Solventum Corporation (SOLV) Q3 2026 Earnings Call Transcript
Although the revenue and EPS for Solventum (SOLV) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Solventum (SOLV) came out with quarterly earnings of $1.45 per share, beating the Zacks Consensus Estimate of $1.35 per share. This compares to earnings of $1.5 per share a year ago.
Benchmark SOLV against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Solventum Corporation (SOLV)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $90.38 | $15.65B | 98.96 | 0.86% | 1.91% | 3.18% | — | |
| $25.79 | $13.32B | -18.55 | 5.72% | -6.23% | -11.67% | 2.63% | |
| $211.88 | $58.38B | 50.76 | -10.91% | 5.66% | 3.67% | 1.96% | |
| $62.36 | $12.16B | 21.15 | 5.06% | 13.46% | 6.88% | — | |
| $1.88 | $7.68M | -0.56 | 814.07% | -795.5% | -162.75% | — | |
| $86.05 | $9.8B | 23.00 | 4.03% | 3.07% | 8.83% | — |
Solventum Corporation (SOLV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Solventum Corporation (SOLV) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Aug 5, 2026·SEC
Jul 20, 2026·SEC
Get notified when SOLV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Solventum Corporation (SOLV) stock FAQ — growth, dividends, profitability & financials explained
Solventum Corporation (SOLV) reported $8.16B in revenue over the trailing twelve months. Revenue was $8.32B in fiscal year 2025. That is 2% more than the $8.17B of fiscal year 2021.
Solventum Corporation (SOLV) revenue fell by 2.8% over the trailing twelve months, compared with the twelve months before.
Yes. Solventum Corporation (SOLV) earned $156.0M in net income over the trailing twelve months (a 1.9% net margin).
Solventum Corporation (SOLV) had a return on equity (ROE) of 3.2% over the trailing twelve months. That is below the market's typical 10-15%.
